- Home
- VINP vs ERAS Comparison
VINP vs ERAS Comparison
Compare VINP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- ERAS
- Stock Information
- Founded
- VINP 2009
- ERAS 2018
- Country
- VINP Brazil
- ERAS United States
- Employees
- VINP N/A
- ERAS N/A
- Industry
- VINP Investment Managers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- ERAS Health Care
- Exchange
- VINP Nasdaq
- ERAS Nasdaq
- Market Cap
- VINP 694.1M
- ERAS 719.0M
- IPO Year
- VINP 2021
- ERAS 2021
- Fundamental
- Price
- VINP $10.34
- ERAS $2.67
- Analyst Decision
- VINP Strong Buy
- ERAS Strong Buy
- Analyst Count
- VINP 2
- ERAS 5
- Target Price
- VINP $14.50
- ERAS $6.10
- AVG Volume (30 Days)
- VINP 60.0K
- ERAS 1.7M
- Earning Date
- VINP 11-07-2024
- ERAS 11-12-2024
- Dividend Yield
- VINP 6.58%
- ERAS N/A
- EPS Growth
- VINP N/A
- ERAS N/A
- EPS
- VINP 0.60
- ERAS N/A
- Revenue
- VINP $88,217,697.00
- ERAS N/A
- Revenue This Year
- VINP $7.69
- ERAS N/A
- Revenue Next Year
- VINP $11.35
- ERAS N/A
- P/E Ratio
- VINP $17.28
- ERAS N/A
- Revenue Growth
- VINP 9.03
- ERAS N/A
- 52 Week Low
- VINP $9.01
- ERAS $1.51
- 52 Week High
- VINP $11.85
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- VINP 49.61
- ERAS 43.56
- Support Level
- VINP $10.51
- ERAS $2.59
- Resistance Level
- VINP $10.95
- ERAS $3.19
- Average True Range (ATR)
- VINP 0.29
- ERAS 0.20
- MACD
- VINP 0.00
- ERAS -0.02
- Stochastic Oscillator
- VINP 32.29
- ERAS 20.13
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.